noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

Results Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation

To initiate joint research aiming to create innovative cancer drugs in Targeted Alpha Therapy［PDF:457.7 KB］

7/9
Mitsubishi Tanabe Pharma Corporation

Appointment of Directors and Executive Officers［PDF:202.1 KB］

6/30
Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma to Begin a New Chapter under Bain Capital Ownership -Company Name Change to “Tanabe Pharma Corporation” Effective December 1, 2025-［PDF:247.8 KB］

6/30
Mitsubishi Tanabe Pharma Corporation

Initiation of Phase 1/2 clinical trial of MT-4561 for Advanced Solid Tumors［PDF:266.0 KB］

6/12
Mitsubishi Tanabe Pharma Corporation

U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease［PDF:204.4 KB］

5/28
Mitsubishi Tanabe Pharma Corporation

Launch of Radicava® for the Treatment of ALS in Australia［PDF:169.7 KB］

5/26
Mitsubishi Tanabe Pharma Corporation

Announcement of Personnel Changes［PDF:242.5 KB］

5/25
Mitsubishi Tanabe Pharma Corporation

Appointment of Directors［PDF:154.3 KB］

5/20
Mitsubishi Tanabe Pharma Corporation

CANAGLU Tablets 100mg, a sodium glucose co-transporter 2 (SGLT2) inhibitor in Thailand Mitsubishi Tanabe Pharma Thailand now started marketing［PDF:356.6 KB］

5/8
Mitsubishi Tanabe Pharma Corporation

Anti CD19 monoclonal antibody UPLIZNAⓇ for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4 related disease in Japan［PDF:435.6 KB］

3/20